Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma

• Published in: Cancers Vol. 12; no. 3; p. 755
• Main Authors: Raghav, Lovely, Chang, Ya-Hsuan, Hsu, Yi-Chiung, Li, Yu-Cheng, Chen, Chih-Yi, Yang, Tsung-Ying, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Chuang, Cheng-Yen, Lee, Mei-Hsuan, Wang, Chih-Liang, Chen, Huei-Wen, Yu, Sung-Liang, Su, Sheng-Fang, Yuan, Shin-Sheng, Chen, Jeremy J.W., Ho, Shinn-Ying, Li, Ker-Chau, Yang, Pan-Chyr, Chang, Gee-Chen, Chen, Hsuan-Yu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.03.2020; MDPI
• Subjects: Adenocarcinoma; Age; Clinical outcomes; Genes; Genomes; Lung cancer; Mitochondria; Mutation; Next-generation sequencing; Patients; Precision medicine; Proteins; Risk factors; Tumors; somatic mutations; prognosis; mitochondria; lung adenocarcinoma; EGFR-activating mutations
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12030755

Risk factors including genetic effects are still being investigated in lung adenocarcinoma (LUAD). Mitochondria play an important role in controlling imperative cellular parameters, and anomalies in mitochondrial function might be crucial for cancer development. The mitochondrial genomic aberrations found in lung adenocarcinoma and their associations with cancer development and progression are not yet clearly characterized. Here, we identified a spectrum of mitochondrial genome mutations in early-stage lung adenocarcinoma and explored their association with prognosis and clinical outcomes. Next-generation sequencing was used to reveal the mitochondrial genomes of tumor and conditionally normal adjacent tissues from 61 Stage 1 LUADs. Mitochondrial somatic mutations and clinical outcomes including relapse-free survival (RFS) were analyzed. Patients with somatic mutations in the D-loop region had longer RFS (adjusted hazard ratio, adjHR = 0.18, p = 0.027), whereas somatic mutations in mitochondrial Complex IV and Complex V genes were associated with shorter RFS (adjHR = 3.69, p = 0.012, and adjHR = 6.63, p = 0.002, respectively). The risk scores derived from mitochondrial somatic mutations were predictive of RFS (adjHR = 9.10, 95%CI: 2.93–28.32, p < 0.001). Our findings demonstrated the vulnerability of the mitochondrial genome to mutations and the potential prediction ability of somatic mutations. This research may contribute to improving molecular guidance for patient treatment in precision medicine.